Lenvatinib mesylate hit both its primary and secondary endpoints in a large Phase III trial comparing it with sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (HCC), Eisai Co. Ltd.'s oral multi-kinase inhibitor in the process becoming the first systemic therapy to show statistical non-inferiority to its marketed rival in terms of median overall survival (OS).
Lenvatinib also showed "statistically significant and clinically meaningful improvements" against a range of secondary endpoints, including progression-free survival (PFS), time...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?